Serum vitamin D levels in relation to schizophrenia: A systematic review and meta-analysis of observational studies

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 10, 2014, Pages 3863-3872

  Valipour, Ghazaleh ^a   Saneei, Parvane ^a   Esmaillzadeh, Ahmad ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYERGOCALCIFEROL; 25 HYDROXYVITAMIN D; CALCIFEDIOL; ERGOCALCIFEROL; HYDROXYCOLECALCIFEROL; VITAMIN D;

ARTICLE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; HEALTH CARE COST; HEALTH CARE SYSTEM; HOSPITALIZATION; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; PREVALENCE; QUALITY CONTROL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; VITAMIN BLOOD LEVEL; VITAMIN D BLOOD LEVEL; VITAMIN D DEFICIENCY; BLOOD; METABOLISM;

HUMANS; OBSERVATIONAL STUDY AS TOPIC; PREVALENCE; SCHIZOPHRENIA; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84907612131     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-1887     Document Type: Article

References (45)

1. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141.
2. Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382(9904):1575-1586.
3. Kinney DK, Teixeira P, Hsu D, et al. Relation of schizophrenia prevalence to latitude, climate, fish consumption, infant mortality, and skin color: a role for prenatal vitamin d deficiency and infections? Schizophr Bull. 2009;35(3):582-595.
4. Davies G, Welham J, Chant D, Torrey EF, McGrath J. A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia. Schizophr Bull. 2003;29(3):587-593.
5. Cantor-Graae E, Selten J-P. Schizophrenia and migration: a metaanalysis and review. Am J Psych. 2005;162(1):12-24.
6. Holick MF. Environmental factors that influence the cutaneous production of vitamin D. Am J Clin Nutr. 1995;61(3):638S-645S.
7. McGrath J, Saari K, Hakko H, et al. Vitamin D supplementation during the first year of life and risk of schizophrenia: a Finnish birth cohort study. Schizophr Res. 2004;67(2-3):237-245.
8. McGrath JJ, Eyles DW, Pedersen CB, et al. Neonatal vitamin D status and risk of schizophrenia: a population-based case-control study. Arch Gen Psychiatry. 2010;67(9):889-894.
9. Itzhaky D, Amital D, Gorden K, Bogomolni A, Arnson Y, Amital H. Low serum vitamin D concentrations in patients with schizophrenia. Isr Med Assoc J. 2012;14(2):88-92.
10. Norelli LJ, Coates AD, Kovasznay BM. A comparison of 25-hydroxyvitamin D serum levels in acute and long-stay psychiatric inpatients: a preliminary investigation. e-SPEN. 2010;5(4):e187-e189.
11. Kendell RE, Adams W. Exposure to sunlight, vitamin D and schizophrenia. Schizophr Res. 2002;54(3):193-198.
12. Murri MB, Respino M, Masotti M, et al. Vitamin D and psychosis: mini meta-analysis. Schizophr Res. 2013;150(1):235-239.
13. McGrath J, Eyles D, Mowry B, Yolken R, Buka S. Low maternal vitamin D as a risk factor for schizophrenia: a pilot study using banked sera. Schizophr Res. 2003;63(1-2):73-78.
14. Boerman R, Cohen D, Schulte P. Do vitamin D levels in bipolar and schizophrenia outpatients differ? Outcome of a Dutch cross-sectional study. Eur Psychiatry. 2013;28:1.
15. Wyszogrodzka-Kucharska A, Rabe-Jablońska J. Calcium balance and regulation in schizophrenic patients treated with second generation antipsychotics. Psychiatr Pol. 2005;39(6):1157-1171.
16. Agarwal S. High incidence of vitamin D deficiency in patients with schizophrenia. [abstract 1367] Eur Psychiatry. 2013;28(suppl1):S1.
17. Agarwal S. Hypovitaminosis D and hypotestosteronemia in schizophrenia patients. [abstract 459] Eur Psychiatry. 2013;28(suppl 1):S1.
18. Kishimoto T, Watanabe K, Shimada N, Makita K, Yagi G, Kashima H. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry. 2008;69(3):385-391.
19. Higuchi T, Komoda T, Sugishita M, et al. Certain neuroleptics reduce bone mineralization in schizophrenic patients. Neuropsychobiology. 1988;18(4):185-188.
20. Schneider B, Weber B, Frensch A, Stein J, Fritz J. Vitamin D in schizophrenia, major depression and alcoholism. J Neural Transm. 2000;107(7):839-842.
21. Abdullah AK, Khan S, Mustafa SF, Qutubuddin AA, Davis CM. Vitamin D status and cardiometabolic risk factors in long-term psychiatric inpatients. Prim Care Companion J Clin Psychiatry. 2012;14(1).
22. Berg AO, Psychol C, Melle I, et al. Across-sectional study of vitamin D deficiency among immigrants and Norwegians with psychosis compared to the general population. J Clin Psychiatry. 2010;71(12):1598-1604.
23. Bergemann N, Parzer P, Mundt C, Auler B. High bone turnover but normal bone mineral density in women suffering from schizophrenia. Psychol Med. 2008;38(8):1195-1201.
24. Cha B, Shin YM, Kim YS, et al. Vitamin D deficiency in schizophrenia, bipolar disorder and major depressive disorder compared to healthy controls. Eur Neuropsychopharmacol. 2011;21:S429-S430.
25. Doknic M, Maric NP, Britvic D, et al. Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated withlong-actinginjectable risperidone. Neuroendocrinology. 2011;94(3):246-254.
26. Humble MB, Gustafsson S, Bejerot S. Low serum levels of 25-hydroxyvitamin D (25-OHD) among psychiatric out-patients in Sweden: relations with season, age, ethnic origin and psychiatric diagnosis. J Steroid Biochem Mol. 2010;121(1-2):467-470.
27. Hummer M, Malik P, Gasser RW, et al. Osteoporosis in patients with schizophrenia. Am J Psych. 2005;162(1):162-167.
28. Jamilian H, Bagherzadeh K, Nazeri Z, Hassanijirdehi M. Vitamin D, parathyroid hormone, serum calcium and phosphorus in patients with schizophrenia and major depression. Int J Psychiatry Clin Pract. 2013;17(1):30-34.
29. Menkes DB, Lancaster K, Grant M, Marsh RW, Dean P, du Toit SA. Vitamin D status of psychiatric inpatients in New Zealand's Waikato region. BMC Psychiatry. 2012;12:68.
30. Murie J, Messow CM, Fitzpatrick B. Feasibility of screening for and treating vitamin D deficiency in forensic psychiatric inpatients. J Forensic Leg Med. 2012;19(8):457-464.
31. Partti K, Heliovaara M, Impivaara O, Perala J, Saarni SI, Lonnqvist J, Suvisaari JM. Skeletal status in psychotic disorders: a populationbased study. Psychosom. Med. 2010;72(9):933-940.
32. Rey-Sánchez P, Lavado-García JM, Canal-Macías ML, Gómez-Zubeldia M, Roncero-Martín R, Pedrera-Zamorano JD. Ultrasound bone mass in schizophrenic patients on antipsychotic therapy. Hum Psychopharmacol. 2009;24(1):49-54.
33. Wyszogrodzka-Kucharska A, Rabe-Jablonska J. Vitamin D deficiency and impaired parathormone metabolism as a risk factor of low bone mineral densityinpatients with diagnosis of schizophrenia treated with second generation antipsychotics. Eur Neuropsychopharmacol. 2006;16:S373-S374.
34. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):13.
35. Wells GA, Shea B, O'Connell D. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses.. University of Ottawa, 2001. Available at http://www.ohri. ca/programs/clinical-epidemiology/oxford.htm. Accessed December 12, 2012.
36. Kesby JP, Eyles DW, Burne TH, McGrath JJ. The effects of vitamin D on brain development and adult brain function. Mol Cell Endocrinol. 2011;347(1-2):121-127.
37. Kiraly SJ, Kiraly MA, Hawe RD, Makhani N. Vitamin D as a neuroactive substance: Review. Scientific World Journal. 2006;6:125-139.
38. McGrath JJ, Burne TH, Feron F, Mackay-Sim A, Eyles DW. Developmental vitamin D deficiency and risk of schizophrenia: a 10-year update. Schizophr Bull. 2010;36(6):1073-1078.
39. Anglin RE, Samaan Z, Walter SD, McDonald SD. Vitamin D deficiency and depression in adults: systematic review and meta-analysis. Br J Psychiatry. 2013;202:100-107.
40. Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr. 2008;87(4):1080S-1086S.
41. Lauth M, Rohnalter V, Bergström Å, Kooshesh M, Svenningsson P, Toftgård R. Antipsychotic drugs regulate hedgehog signaling by modulation of 7-dehydrocholesterol reductase levels. Mol Pharmacol. 2010;78(3):486-496.
42. Kesby JP, Cui X, Burne TH, Eyles DW. Altered dopamine ontogeny in the developmentally vitamin D deficient rat and its relevance to schizophrenia. Front Cell Neurosci. 2013;7:111.
43. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version iii-the final common pathway. Schizophr Bull. 2009;35(3):549-562.
44. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001;62(suppl 7):22-31.
45. Saneei P, Salehi-Abargouei A, Esmaillzadeh A. Serum 25-hydroxy vitamin D levels in relation to body mass index: a systematic review and meta-analysis. Obes Rev. 2013;14(5):393-404.